Brolucizumab (Beovu, *Novartis*) was recently approved by the US FDA in October 2019 for the treatment of neovascular age-related macular degeneration (n-AMD). Brolucizumab is a 28 kDa humanized single chain antibody fragment (scFv) molecule that binds to all isoforms of VEGF-A and renders them ineffective \[[@CR1]\].

Drying of fluid in the macula has been one of the major clinical end points for the management of n-AMD \[[@CR2]\]. The clinical significance of fluid depends on its location {intraretinal (IRF) or subretinal (SRF) or beneath the retinal pigment epithelium (sub-RPE)} \[[@CR3]\]. However, pathology that leads to the formation of fluid has a major role in determining the long term success of the treatment.

Brolucizumab was approved on the basis of the pivotal phase three clinical trial results of the HAWK and HARRIER studies. The visual gains were found to be noninferior to aflibercept at 1 year. It was further maintained at the end of 2 years. Visual gains of +6.6 letters in 6 mg brolucizumab group compared with +6.8 letters with 2 mg aflibercept in HAWK trial was maintained at 2 years with 5.9 letters and 5.3 letters, respectively. Similarly, a gain of +6.9 letters with 6 mg brolucizumab, when compared with +7.6 letters with aflibercept in HARRIER, was maintained as 6.1 letters versus 6.6 letters, respectively.

Although visual gain was the primary outcome through a 96-week follow-up period, fluid assessment in the form of central subfield thickness (CST) and the IRF/SRF was considered as a key, secondary outcome of these trials. At week 48, 31.2% of patients in 6 mg brolucizumab group had IRF/SRF compared with 44.6% in aflibercept in the HAWK trial and HARRIER showed IRF/SRF in 25.8% (brolucizumab) and 43.9% (aflibercept) patients. At 96 weeks, 24% and 37% of the patients had persistent IRF/SRF in HAWK trials for 6 mg brolucizumab and aflibercept, respectively. HARRIER showed a persistence rate of 24% (brolucizumab) and 39% (aflibercept) patients. At 96 weeks, 11% of patients in brolucizumab 6 mg group had sub-RPE fluid compared with 15% in aflibercept group in HAWK. It was 17% and 22%, respectively, in HARRIER trial. Furthermore, the mean change in CST from baseline graph by optical coherence tomography over time was found to be less variable as compared to the seesaw pattern observed with the aflibercept control arm. Lesser fluctuation in the CST is an indicator of better fluid control which could be beneficial for the health of the retinal tissue in the long term \[[@CR4]\].

Superior fluid control across all the fluid types (IRF/SRF/sub-RPE) needs further understanding about the probable mechanism. Earlier trials such as CATT and EXCITE have demonstrated that the presence of IRF is an indicator of a later decline in visual acuity \[[@CR3], [@CR5]\]. However, fluid should not be seen as an isolated entity, rather it should be analyzed in terms of the pathology causing it such as type 1, 2, or 3 macular neovascularization (MNV) \[[@CR6]\]. The better control of IRF/SRF/sub-RPE fluid with brolucizumab might have contributed to the \>50% proportion of patients maintaining q12w dosing through 1 year of follow-up \[[@CR4]\]. The US FDA has approved a 12-week dosing schedule for the molecule after three monthly loading doses.

To further understand the superior fluid control with brolucizumab, it is important to understand the molecular structure. Brolucizumab was developed by grafting complementarity-determining regions of the novel anti-VEGF antibody to a human scFv scaffold. ScFvs are the smallest functional unit of an antibody, allowing the delivery of a greater molar dose into the vitreous cavity compared with larger molecules \[[@CR1]\]. This might provide better diffusion into tissue. The pre-clinical data revealed that the retina had a 2.2 times higher exposure to the molecule when compared with ranibizumab. RPE/Choroid complex also had 1.7 times higher exposure. Smaller size and higher molecular concentration might help to increase the duration of fluid control \[[@CR4]\].

Fluid in n-AMD should be analyzed in relation to the original pathology. Sub-RPE fluid is predominantly caused by type 1 MNV or polypoidal disease whereas SRF and IRF are more common in type 2 MNV. Type 2 MNV would cause SRF in the early stages. After the external limiting membrane barrier is broken, fluid seeps into the intraretinal space. Therefore, the location of fluid indirectly indicates the stage of the disease. Presence of IRF leading to later decline in visual acuity refers to the advanced stage of the disease. However, type 3 MNV {retinal angiomatous proliferation (RAP)} can vary in this aspect \[[@CR6]\].

The impact of brolucizumab on IRF/SRF and sub-RPE fluid has been analyzed in the HAWK and HARRIER studies. However, IRF and SRF were not analyzed in isolation. None of the prospective trials in the past have differentiated the types of fluid. Analysis of IRF, SRF, and sub-RPE fluid as separate entities might be more meaningful to understand the effect of brolucizumab on the theoretical concern of geographic atrophy due to enhanced drying. There are practical difficulties to find sufficient number of cases with compartmentalized fluid in trials. Real world large data sets might be helpful to help sort out these unanswered questions.

Landmark trials for n-AMD support regular monthly or bimonthly injections of anti-VEGF therapy to maintain vision \[[@CR7]--[@CR9]\]. This treatment regimen is difficult for patients to adhere to, as reflected in several real world treatment studies. Visual gains and the number of injections were significantly lower in real world compared to the gains demonstrated in well designed anti-VEGF therapy clinical trials \[[@CR10], [@CR11]\]. Jeff et al. demonstrated that eyes with early persistent retinal fluid (after three loading doses of ranibizumab) would require frequent injections to have better outcomes. After a decade of anti-VEGF use in the management of n-AMD, the goal of treatment has shifted to explore the treatment strategies to reduce the injection burden by reducing the frequency of injections. Brolucizumab performance in clinical trials suggests that it might help retinal specialists address two continuing issues of anti-VEGF therapy: persistent retinal fluid despite treatment, and the burden on patients of frequent anti-VEGF injections. Brolucizumab seems to be a promising new generation anti-VEGF molecule based on the trial results. However, real world data are yet to confirm the same.
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